

Paola NisticÃ²

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9292611/publications.pdf>

Version: 2024-02-01

63
papers

2,881
citations

218592

26
h-index

175177

52
g-index

69
all docs

69
docs citations

69
times ranked

4252
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Epithelial-Mesenchymal Transition: General Principles and Pathological Relevance with Special Emphasis on the Role of Matrix Metalloproteinases. <i>Cold Spring Harbor Perspectives in Biology</i> , 2012, 4, a011908-a011908. | 2.3 | 231 |
| 2 | Cross-reactivity between tumor MHC class II-restricted antigens and an enterococcal bacteriophage. <i>Science</i> , 2020, 369, 936-942. | 6.0 | 217 |
| 3 | β 4 and β 1 Integrins Associate with ErbB-2 in Human Carcinoma Cell Lines. <i>Experimental Cell Research</i> , 1997, 236, 76-85. | 1.2 | 201 |
| 4 | Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 89. | 3.5 | 157 |
| 5 | Circulating Autoantibodies to Phosphorylated α -Enolase are a Hallmark of Pancreatic Cancer. <i>Journal of Proteome Research</i> , 2011, 10, 105-112. | 1.8 | 119 |
| 6 | An integrated humoral and cellular response is elicited in pancreatic cancer by α -enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. <i>International Journal of Cancer</i> , 2009, 125, 639-648. | 2.3 | 115 |
| 7 | Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 19280-19285. | 3.3 | 112 |
| 8 | Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo. <i>Clinical and Experimental Metastasis</i> , 2009, 26, 153-159. | 1.7 | 107 |
| 9 | Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. <i>International Journal of Cancer</i> , 2009, 124, 130-139. | 2.3 | 103 |
| 10 | Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. <i>Journal of Hematology and Oncology</i> , 2017, 10, 16. | 6.9 | 101 |
| 11 | Polyphenols: Immunomodulatory and Therapeutic Implication in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 729. | 2.2 | 101 |
| 12 | Autoantibody Signature in Human Ductal Pancreatic Adenocarcinoma. <i>Journal of Proteome Research</i> , 2007, 6, 4025-4031. | 1.8 | 88 |
| 13 | Molecular Cloning of hMena (ENAH) and Its Splice Variant hMena+11a: Epidermal Growth Factor Increases Their Expression and Stimulates hMena+11a Phosphorylation in Breast Cancer Cell Lines. <i>Cancer Research</i> , 2007, 67, 2657-2665. | 0.4 | 80 |
| 14 | Human mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+T-cell immune response. <i>International Journal of Cancer</i> , 2004, 109, 909-918. | 2.3 | 78 |
| 15 | 3D models in the new era of immune oncology: focus on T cells, CAF and ECM. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 117. | 3.5 | 78 |
| 16 | The Cytoskeleton Regulatory Protein hMena (ENAH) Is Overexpressed in Human Benign Breast Lesions with High Risk of Transformation and Human Epidermal Growth Factor Receptor-2-Positive/Hormonal Receptor-Negative Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 1470-1478. | 3.2 | 73 |
| 17 | Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 67-77. | 3.2 | 71 |
| 18 | Fibronectin as a multiregulatory molecule crucial in tumor matrisome: from structural and functional features to clinical practice in oncology. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 102. | 3.5 | 64 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines. <i>Clinical Cancer Research</i> , 2008, 14, 4943-4950. | 3.2 | 63 |
| 20 | Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist. <i>Oncogene</i> , 2015, 34, 2493-2504. | 2.6 | 59 |
| 21 | Dacarbazine Treatment before Peptide Vaccination Enlarges T-Cell Repertoire Diversity of Melan-A-Specific, Tumor-Reactive CTL in Melanoma Patients. <i>Cancer Research</i> , 2010, 70, 7084-7092. | 0.4 | 57 |
| 22 | Î²1 and Î²4 integrins: from breast development to clinical practice. <i>Breast Cancer Research</i> , 2014, 16, 459. | 2.2 | 57 |
| 23 | Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. <i>Journal of Hematology and Oncology</i> , 2013, 6, 67. | 6.9 | 42 |
| 24 | Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens. <i>Communications Biology</i> , 2020, 3, 85. | 2.0 | 36 |
| 25 | Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients. <i>Journal of Translational Medicine</i> , 2009, 7, 21. | 1.8 | 32 |
| 26 | Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. <i>Oncotarget</i> , 2014, 5, 11054-11063. | 0.8 | 32 |
| 27 | Polyfunctional Melan-A-specific tumor-reactive CD8 ⁺ T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS. <i>Oncolmmunology</i> , 2016, 5, e1114203. | 2.1 | 25 |
| 28 | Modulation of the antigenic phenotype of early-passage human melanoma cells derived from multiple autologous metastases by recombinant human leukocyte, fibroblast and immune interferon. <i>International Journal of Cancer</i> , 1990, 46, 539-545. | 2.3 | 24 |
| 29 | Molecular and Genetic Bases of Pancreatic Cancer. <i>Current Drug Targets</i> , 2012, 13, 731-743. | 1.0 | 24 |
| 30 | The pattern of hMENA isoforms is regulated by TGF-Î²1 in pancreatic cancer and may predict patient outcome. <i>Oncolmmunology</i> , 2016, 5, e1221556. | 2.1 | 23 |
| 31 | IL-18 receptor marks functional CD8 ⁺ T cells in non-small cell lung cancer. <i>Oncolmmunology</i> , 2017, 6, e1328337. | 2.1 | 23 |
| 32 | The Cooperation between hMena Overexpression and HER2 Signalling in Breast Cancer. <i>PLoS ONE</i> , 2010, 5, e15852. | 1.1 | 23 |
| 33 | Imaging laser diffractometer for traceable grating pitch calibration. <i>Measurement Science and Technology</i> , 2007, 18, 375-383. | 1.4 | 22 |
| 34 | hMENA is a key regulator in endothelin-1/Î²-arrestin1-induced invadopodial function and metastatic process. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 3132-3137. | 3.3 | 21 |
| 35 | Gene transfer by retrovirus-derived shuttle vectors in the generation of murine bispecific monoclonal antibodies.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 2941-2945. | 3.3 | 20 |
| 36 | The actin modulator hMENA regulates GAS6-AXL axis and promotes tumor cancer/stromal cell cooperation. <i>EMBO Reports</i> , 2020, 21, e50078. | 2.0 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | hMENA isoforms impact NSCLC patient outcome through fibronectin/ β 1 integrin axis. <i>Oncogene</i> , 2018, 37, 5605-5617. | 2.6 | 17 |
| 38 | Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy. <i>Journal of Translational Medicine</i> , 2019, 17, 131. | 1.8 | 17 |
| 39 | Actin Cytoskeleton and Regulation of TGF β 2 Signaling: Exploring Their Links. <i>Biomolecules</i> , 2021, 11, 336. | 1.8 | 17 |
| 40 | Melan-A/MART-1 Antigen Expression in Cutaneous and Ocular Melanomas. <i>Journal of Immunotherapy</i> , 1997, 20, 466-469. | 1.2 | 15 |
| 41 | Biological mechanisms linked to inflammation in cancer: Discovery of tumor microenvironment-related biomarkers and their clinical application in solid tumors. <i>International Journal of Biological Markers</i> , 2020, 35, 8-11. | 0.7 | 15 |
| 42 | Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma.. <i>Journal of Clinical Investigation</i> , 1992, 90, 1093-1099. | 3.9 | 15 |
| 43 | Low Frequency of ErbB-2 Proto-oncogene Overexpression in Human Leukocyte Antigen-A2-Positive Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 1997, 89, 319-321. | 3.0 | 13 |
| 44 | hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells. <i>Oncogene</i> , 2016, 35, 887-896. | 2.6 | 13 |
| 45 | Host immunosurveillance contributes to the control of erbB-2 overexpression in HLA-A2-breast-cancer patients. <i>International Journal of Cancer</i> , 1999, 84, 598-603. | 2.3 | 12 |
| 46 | Generation and characterization of two human alpha/beta T cell clones. Recognizing autologous breast tumor cells through an HLA- and TCR/CD3-independent pathway.. <i>Journal of Clinical Investigation</i> , 1994, 94, 1426-1431. | 3.9 | 9 |
| 47 | MHC-Peptide Binding. <i>Journal of Immunotherapy</i> , 1997, 20, 431-436. | 1.2 | 8 |
| 48 | Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Na \tilde{A} ve/Memory T Cell Immunomonitoring. <i>Journal of Immunology Research</i> , 2020, 2020, 1-15. | 0.9 | 8 |
| 49 | Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients. <i>OncImmunology</i> , 2018, 7, e1465163. | 2.1 | 6 |
| 50 | Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. <i>Frontiers in Oncology</i> , 2020, 10, 202. | 1.3 | 6 |
| 51 | Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 471-486. | 1.1 | 5 |
| 52 | hMENA ^{11a} , a hMENA isoform sending survival signals. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1083648. | 0.3 | 2 |
| 53 | Actin Cytoskeleton Dynamics and Type I IFN-Mediated Immune Response: A Dangerous Liaison in Cancer?. <i>Biology</i> , 2021, 10, 913. | 1.3 | 2 |
| 54 | Abstract 4316: hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2 overexpressing breast cancer cells. , 2015, , . | | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Prognostic impact of the cytoskeleton regulatory protein hMena in resected node-negative non-small cell lung cancer (NSCLC): A clinical-biological risk stratification model.. Journal of Clinical Oncology, 2010, 28, 7027-7027. | 0.8 | 1 |
| 56 | Polyclonal Antibodies Against gp185HER2 Peptides: Their Putative Role in the Identification of a Particular HER2 Status in Patients With Breast Cancer. Journal of Immunotherapy, 2001, 24, 221-231. | 1.2 | 0 |
| 57 | hMENA splicing program impacts the clinical outcome of early stage lung cancer patients. How and why?. Journal of Translational Medicine, 2014, 12, . | 1.8 | 0 |
| 58 | A cytofluorimetric assay to evaluate T cell polyfunctionality. Methods in Enzymology, 2020, 631, 61-76. | 0.4 | 0 |
| 59 | Abstract 4406: Clinical efficacious combined chemo/immunotherapy differently activates AKT pathway and functionality of gp100 and Melan-A specific T cell clones. , 2012, , . | | 0 |
| 60 | Abstract 1035: hMENA splicing program and TGF- β 21-mediated EMT in pancreatic cancer. , 2014, , . | | 0 |
| 61 | Abstract A60: The hMENA Splicing Program: An important regulator of TGF β 21-driven EMT and invasiveness in pancreatic cancer. , 2015, , . | | 0 |
| 62 | Abstract A003: Polyfunctional antitumor CD8 T cells obtained from a broad repertoire elicited by chemo-immunotherapy and preventing melanoma relapse depends on the activation of an AKT pathway sustained by ICOS. , 2016, , . | | 0 |
| 63 | Abstract A113: The pattern of hMENA isoforms is regulated by TGF- β 21 in pancreatic cancer and may predict patient outcome. , 2016, , . | | 0 |